27 October 2020
("Instem", the "Company" or the "Group")
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, will be hosting a presentation through the digital platform, Investor Meet Company, at 16.30 on the afternoon of 04 November 2020.
The Company will discuss recent results, where it provided an update on trading and progress on its acquisition strategy following the July 2020 fundraise. It will also discuss divisional developments, specifically within the areas of Informatics and SEND (the Standard for the Exchange of Non-clinical Data). No new price sensitive information will be provided.
Questions can be submitted pre-event to email@example.com or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. Responses to the Q&A from the live presentation will be published at the earliest opportunity on the IMC platform.
Investors can sign up to Investor Meet Company for free and add to meet Instem via the following link https://investormeetcompany.com/instem-plc/register-investor
Those investors who have already registered with Investor Meet Company will automatically be invited.
A copy of the presentation will be made available on the Company’s website shortly after the presentation.
For further information, please contact:
|Instem plc||Via Walbrook|
|Phil Reason, CEO|
|Nigel Goldsmith, CFO|
|N+1 Singer (Nominated Adviser & Broker)||+44 (0) 20 7496 3000|
|Wallbrook Financial PR||Tel: +44 (0) 20 7933 8780|
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.
Instem solutions are in use by over 500 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.
To learn more about Instem solutions and its mission, please visit www.instem.com